[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @OzmosiHealth Ozmosi Ozmosi posts on X about more info, $pph, $xph, $ibb the most. They currently have XXXXX followers and XXX posts still getting attention that total XXXXXX engagements in the last XX hours. ### Engagements: XXXXXX [#](/creator/twitter::1055982930/interactions)  - X Week XXXXXX +84% - X Month XXXXXXX +41% - X Months XXXXXXX +7.10% - X Year XXXXXXXXX +82% ### Mentions: XX [#](/creator/twitter::1055982930/posts_active)  - X Month XXX -XX% - X Months XXXXX +20% - X Year XXXXX +61% ### Followers: XXXXX [#](/creator/twitter::1055982930/followers)  - X Week XXXXX +8.80% - X Month XXXXX +11% - X Months XXXXX +24% - X Year XXXXX +42% ### CreatorRank: XXXXXXX [#](/creator/twitter::1055982930/influencer_rank)  ### Social Influence [#](/creator/twitter::1055982930/influence) --- **Social category influence** [stocks](/list/stocks) XXXX% [countries](/list/countries) XXXX% [currencies](/list/currencies) XXXX% [cryptocurrencies](/list/cryptocurrencies) XXXX% [finance](/list/finance) XXXX% **Social topic influence** [more info](/topic/more-info) #96, [$pph](/topic/$pph) #1, [$xph](/topic/$xph) #1, [$ibb](/topic/$ibb) #1, [$xbi](/topic/$xbi) #1, [$abvx](/topic/$abvx) #6, [$rhhby](/topic/$rhhby) 0.41%, [$cytk](/topic/$cytk) 0.41%, [canada](/topic/canada) 0.41%, [$ivbiy](/topic/$ivbiy) XXXX% **Top accounts mentioned or mentioned by** [@marketwirenews](/creator/undefined) [@salmanfirat2](/creator/undefined) [@towiu2](/creator/undefined) [@john06746191](/creator/undefined) [@stewdomer](/creator/undefined) [@dwill3000](/creator/undefined) [@chrismangum14](/creator/undefined) [@nicolem52807658](/creator/undefined) [@mitchellreed09](/creator/undefined) **Top assets mentioned** [Bitcoin Incognito (XBI)](/topic/$xbi) [Cytokinetics Inc. (CYTK)](/topic/$cytk) [Crinetics Pharmaceuticals, Inc. (CRNX)](/topic/$crnx) [Bristol-Myers Squibb Co (BMY)](/topic/$bmy) [Biogen Inc (BIIB)](/topic/$biib) [Halozyme Therapeutics, Inc. (HALO)](/topic/$halo) [Merck & Co., Inc. (MRK)](/topic/$mrk) [Krystal Biotech, Inc. Common Stock (KRYS)](/topic/$krys) [Neurocrine Biosciences, Inc. (NBIX)](/topic/$nbix) [Alnylam Pharmaceuticals, Inc. (ALNY)](/topic/$alny) [Madrigal Pharmaceuticals, Inc. Common Stock (MDGL)](/topic/$mdgl) [SuperRare (RARE)](/topic/$rare) [Corcept Therapeutics Inc. (CORT)](/topic/$cort) [QuidelOrtho Corporation Common Stock (QDEL)](/topic/$qdel) [Incyte Corporation (INCY)](/topic/$incy) [IDEAYA Biosciences, Inc. Common Stock (IDYA)](/topic/$idya) [SpringWorks Therapeutics, Inc. Common Stock (SWTX)](/topic/$swtx) [Protagonist Therapeutics, Inc (PTGX)](/topic/$ptgx) [Ionis Pharmaceuticals, Inc. Common Stock (IONS)](/topic/$ions) [Eli Lilly and Company (LLY)](/topic/$lly) [Geron Corp (GERN)](/topic/$gern) [Gilead Sciences, Inc. (GILD)](/topic/$gild) [Hims & Hers Health, Inc. (HIMS)](/topic/$hims) [AstraZeneca PLC (AZN)](/topic/$azn) ### Top Social Posts [#](/creator/twitter::1055982930/posts) --- Top posts by engagements in the last XX hours "HanchorBio moves forward with global impact of HCB101 immunotherapy. Listed on TPEx. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945476613271150748) 2025-07-16 13:32:24 UTC 2610 followers, XXX engagements "$CRDL TSX:CRDL Cardiol Therapeutics locks database for Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947620686476021854) 2025-07-22 11:32:11 UTC 2622 followers, XXX engagements "$RHHBY Roche's latest announcement provides an update on the use of astegolimab in treating chronic obstructive pulmonary disease in accordance with Art. XX LR. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947175365182730374) 2025-07-21 06:02:38 UTC 2623 followers, XXX engagements "$NRSN Join Aaron Lazar and NeuroSense CEO Alon Ben-Noon in a live podcast discussing ALS science PrimeC's strategies and community impact. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947643337483112663) 2025-07-22 13:02:11 UTC 2623 followers, XXX engagements "$CRNX Crinetics will present new long-term data showing lasting control of oral PALSONIFY in Acromegaly at ENDO 2025. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1944517755635630449) 2025-07-13 22:02:14 UTC 2613 followers, XXX engagements "$BMY Bristol Myers Squibb's sNDA for Sotyktu (deucravacitinib) in treating active Psoriatic Arthritis accepted for review in four regions worldwide. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947250723793866964) 2025-07-21 11:02:05 UTC 2615 followers, XXX engagements "$HALO Halozyme reports argenx gains EU approval for VYVGART subcutaneous injection with ENHANZE to treat CIDP. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1936115212270325991) 2025-06-20 17:33:32 UTC 2619 followers, XXX engagements "WHO adds ArkBio's Ziresovir to list of priority drugs for pediatric RSV. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945295410538619297) 2025-07-16 01:32:22 UTC 2610 followers, XXX engagements "$OKYO OKYO Pharma announces promising Phase X trial data for Urcosimod in treating Neuropathic Corneal Pain. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945476605067063570) 2025-07-16 13:32:22 UTC 2613 followers, XXX engagements "🚀🚨 BIOPHARM CATALYST ALERT 📆 $CRNX Crinetics will present Phase X Adrenal Hyperplasia Congenital Data for Atumelnant (MCR Antagonist - Small Molecule) tomorrow 👀"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1943629425394045011) 2025-07-11 11:12:20 UTC 2623 followers, XXX engagements "Fast-track designation granted by FDA for DualityBio's Next-Generation HER3 ADC DB-1310. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947484861507506475) 2025-07-22 02:32:28 UTC 2622 followers, XXX engagements "$APTOF TSX:APS Aptose gets second advance from Hanmi Pharmaceutical for Tuspetinib development in AML triplet therapy. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945235025827651995) 2025-07-15 21:32:25 UTC 2620 followers, XXX engagements "$CYTK Cytokinetics reveals more info on Aficamten at ESC Heart Failure 2025 Congress. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1924080655564173725) 2025-05-18 12:32:30 UTC 2622 followers, 1167 engagements "$ONCY TSX:ONC Oncolytics Biotech showcases translated data showing Pelareorep's effectiveness in various tumor types. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945469347247616416) 2025-07-16 13:03:32 UTC 2613 followers, XXX engagements "$ELDN New findings from Eledon Pharmaceuticals' Phase 1b trial of Tegoprubart in kidney transplant patients will be shared at World Transplant Congress 2025. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945944826559729743) 2025-07-17 20:32:55 UTC 2616 followers, XXX engagements "$OGEN Oragenics Inc. reveals drug manufacturing deal in the U.S. to aid ONP-002 clinical progress. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945469369078956430) 2025-07-16 13:03:37 UTC 2615 followers, XXX engagements "$ALDX Aldeyra Therapeutics' NDA for Reproxalap in treating Dry Eye Disease accepted by FDA for review. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945808936600514875) 2025-07-17 11:32:56 UTC 2613 followers, XXX engagements "$MRK Health Canada approved KEYTRUDA to treat adult patients with FIGO 2014 Stage III-IVA cervical cancer alongside chemoradiotherapy (CRT). More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947318700291535210) 2025-07-21 15:32:12 UTC 2623 followers, XXX engagements "$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X trials of Obefazimod in treating moderate-severe ulcerative colitis. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947832210083746182) 2025-07-23 01:32:42 UTC 2623 followers, XXX engagements "$IVBIY In 2025 Innovent Biologics will present updated data on IBI363 (PD-1/IL-2-bias Bispecific Antibody Fusion Protein) in Phase X trials for advanced colorectal cancer. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1929335353519071613) 2025-06-02 00:32:48 UTC 2622 followers, XXX engagements "$KRYS First patient dosed in Phase 1/2 trial of KB801 for Neurotrophic Keratitis treatment announces Krystal Biotech. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1942909752713134281) 2025-07-09 11:32:37 UTC 2614 followers, XXX engagements "$AQST Aquestive Therapeutics announces update on international expansion for Anaphylm (epinephrine) Sublingual Film. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945076465957265422) 2025-07-15 11:02:21 UTC 2623 followers, XXX engagements "Sun Pharma introduces LEQSELVI (deuruxolitinib) in the US for severe Alopecia Areata treatment. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1944721646767771737) 2025-07-14 11:32:26 UTC 2614 followers, XXX engagements "$SXTP SXTPW XX Degrees Pharmaceuticals and Tulane University collaborate for research on Tafenoquine against Lyme and Bartonella bacteria. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945823913403158638) 2025-07-17 12:32:27 UTC 2616 followers, XXX engagements "$LTRN Lantern Pharma gets EU patent for LP-284 strengthening global IP for AI-designed cancer treatment. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947273433890599143) 2025-07-21 12:32:19 UTC 2622 followers, XXX engagements "$ARGX argenx progresses clinical development of ARGX-119 for Congenital Myasthenic Syndromes. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1939557671314817282) 2025-06-30 05:32:38 UTC 2613 followers, XXX engagements "$CGEN First patient dosed in COM701 Global Platform Trial for Platinum Sensitive Ovarian Cancer announced by Compugen. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947258356433089004) 2025-07-21 11:32:25 UTC 2614 followers, XXX engagements "Ultomiris drug market projected to reach USD XXXXX billion by 2034 with a CAGR of 31.52%. Report covers analysis trends forecast segmentation growth rate and SWOT analysis. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945340738432327841) 2025-07-16 04:32:29 UTC 2610 followers, XXX engagements "$IVBIY Phase X results of Innovent Biologics' IBI343 for advanced gastric/esophageal adenocarcinoma published in Nature Medicine. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945642697097908598) 2025-07-17 00:32:21 UTC 2620 followers, XXX engagements "AGT announces promising results from AGT103-T HIV Functional Cure Program presented as late-breaker at International AIDS Society 2025. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947681148131586117) 2025-07-22 15:32:26 UTC 2623 followers, XXX engagements "$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X outcomes for ABTECT trials on Obefazimod an oral miR-124 enhancer for moderate to severe ulcerative colitis. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947839761181512142) 2025-07-23 02:02:42 UTC 2623 followers, XXX engagements "$NBIX Neurocrine Biosciences reveals 1-year data demonstrating sustained effectiveness of CRENESSITY (crinecerfont) in adult patients at ENDO 2025. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1944744285708206082) 2025-07-14 13:02:23 UTC 2622 followers, XXX engagements "$ABVX PARIS:ABVX PARIS:FR Abivax reports encouraging Phase X results from ABTECT trials on Obefazimod for moderate to severe ulcerative colitis. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947764286136455425) 2025-07-22 21:02:48 UTC 2623 followers, 1396 engagements "Nanoscope Therapeutics begins submitting BLA to FDA for MCO-010 the first gene-agnostic therapy for Retinitis Pigmentosa. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1944721677113585687) 2025-07-14 11:32:33 UTC 2614 followers, XXX engagements "$RDHL FDA provides positive feedback on RedHill's pathway for approval of RHB-204 for Crohn's Disease a groundbreaking treatment. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947288537310933176) 2025-07-21 13:32:20 UTC 2615 followers, XXX engagements "$FBIO MBIO U.S. FDA grants Orphan Drug Designation to Mustang Bio for MB-101 to treat Astrocytomas and Glioblastoma with IL13Ra2-targeted CAR T-cells. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1942207549711032351) 2025-07-07 13:02:18 UTC 2613 followers, XXX engagements "$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X results in ABTECT trials for Obefazimod in moderate to severe ulcerative colitis. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947809437676408951) 2025-07-23 00:02:13 UTC 2623 followers, XXX engagements "$BRCTF Lecanemab's drug discovery research receives 9th Bioindustry Award from Japan Bioindustry Association. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945393526902284520) 2025-07-16 08:02:15 UTC 2610 followers, XXX engagements "$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X outcomes in ABTECT trials using Obefazimod for ulcerative colitis. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947794374701793596) 2025-07-22 23:02:21 UTC 2623 followers, XXX engagements "$BIIB STOK Biogen and Stoke Therapeutics will share data on Zorevunersen for Dravet syndrome at the EPNS Congress. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1943279659543859447) 2025-07-10 12:02:29 UTC 2622 followers, XXX engagements "DCA opens today to enhance Asia's data center network. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947243223421988895) 2025-07-21 10:32:17 UTC 2620 followers, XXX engagements "$KMSTF NLSP NLS Pharmaceutics reports progress in iTOL-102 program as BIRD Foundation approves payment to Kadimastem and iTolerance for Type X Diabetes therapy development. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945808960352903268) 2025-07-17 11:33:02 UTC 2613 followers, XXX engagements "$HOTH Hoth Therapeutics partners with VA for GDNF research targeting obesity and fatty liver. Study underway comparing GDNF to Semaglutide. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947635807444959541) 2025-07-22 12:32:16 UTC 2623 followers, XXX engagements "$PMN U.S. FDA grants ProMIS Neurosciences Fast Track Designation for PMN310 in Alzheimer's Disease treatment. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947273427477549322) 2025-07-21 12:32:18 UTC 2620 followers, XXX engagements "Reunion Neuroscience reports publication of RE104 Phase X Data in The Journal of Clinical Psychopharmacology. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947620693241434545) 2025-07-22 11:32:12 UTC 2622 followers, XXX engagements "First patient enrolled in Phase 2a trial of 4P004 by Moving Biotech for knee osteoarthritis. 4P004 is a potential first-in-class GLP-1 therapy. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945348235113193734) 2025-07-16 05:02:16 UTC 2613 followers, XXX engagements "🚀🚨 BIOPHARM CATALYST ALERT 📆 $CYTK Cytokinetics will present P3 Cardiomyopathy Hypertrophic Data for Aficamten (MYBPC3 Inhibitor - Small Molecule) tomorrow 👀"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1923698096132981081) 2025-05-17 11:12:21 UTC 2622 followers, XXX engagements "Genascence receives FDA approval for GNSC-001 as a Regenerative Medicine Advanced Therapy for Knee Osteoarthritis (OA) in the U.S. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945453994773745785) 2025-07-16 12:02:31 UTC 2610 followers, XXX engagements "$RCKT RCKT stock plunges due to FDA Clinical Hold on RP-A501 trial sparking Class Action by Hagens Berman. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945929703132729508) 2025-07-17 19:32:49 UTC 2613 followers, XXX engagements "$GLUE Phase X study of MRT-8102 a NEK7-Directed Molecular Glue Degrader for treating inflammatory diseases begins with dosing of first subjects by Monte Rosa Therapeutics. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947258369326334140) 2025-07-21 11:32:28 UTC 2615 followers, XXX engagements "$CASI CASI Pharmaceuticals names David Cory as CEO to lead U.S. company focusing on CID-103 clinical development a promising Anti-CD38 program. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947394246950195463) 2025-07-21 20:32:23 UTC 2622 followers, XXX engagements "$AGEN GSK GSK's SHINGRIX now approved by US FDA in prefilled syringe. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945808945345622404) 2025-07-17 11:32:58 UTC 2613 followers, XXX engagements "$ASND Updated Phase X results show continued positive response to TransCon PTH treatment for adults with hypoparathyroidism with benefits in biochemistries kidney function and quality of life. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1944857538438303976) 2025-07-14 20:32:25 UTC 2607 followers, XXX engagements "$ALNY OXLUMO (lumasiran injection) is now reimbursed in Canada for treating Primary Hyperoxaluria Type X (PH1) in pediatric and adult patients. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1940456256696996052) 2025-07-02 17:03:18 UTC 2613 followers, XXX engagements "$MDGL Madrigal Pharmaceuticals has been granted a new U.S. patent by the Patent and Trademark Office for Rezdiffra (Resmetirom). More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945461508689064259) 2025-07-16 12:32:23 UTC 2613 followers, XXX engagements "Government endorses SNB-101 as promising Small Cell Lung Cancer therapy. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945461515370598521) 2025-07-16 12:32:24 UTC 2610 followers, XXX engagements "$RARE Ultragenyx gets Breakthrough Therapy status for GTX-102 in Angelman Syndrome. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1938576148390400183) 2025-06-27 12:32:25 UTC 2622 followers, XXX engagements "Diakonos Oncology reports first patient dosed in Phase X trial of DOC1021 for Glioblastoma. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947635820032032822) 2025-07-22 12:32:19 UTC 2622 followers, XXX engagements "ReAlta Life Sciences releases data showing RLS-0071 decreases brain inflammation in preclinical hypoxic ischemic encephalopathy model. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947635814181310641) 2025-07-22 12:32:18 UTC 2622 followers, XXX engagements "$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X outcomes for ABTECT trials on Obefazimod in treating Ulcerative Colitis. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947786816930910555) 2025-07-22 22:32:19 UTC 2623 followers, XXX engagements "$KROS Keros Therapeutics initiates Phase X RENEW Clinical Trial of Elritercept with first patient dosing announced. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945823922462900330) 2025-07-17 12:32:29 UTC 2613 followers, XXX engagements "$KZR FDA lifted partial clinical hold on PORTOLA Phase 2a Trial of Zetomipzomib for Autoimmune Hepatitis by Kezar Life Sciences. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945227456832737770) 2025-07-15 21:02:20 UTC 2610 followers, XXX engagements "First patient dosed by OncoC4 with potential best-in-class PD-1/VEGF bispecific antibody AI-081 in Phase X of BIPAVE-001 trial for solid tumors in US. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947620709531889789) 2025-07-22 11:32:16 UTC 2622 followers, XXX engagements "$CORT New Drug Application submitted by Corcept for Relacorilant intended for patients with Platinum-Resistant Ovarian Cancer. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1944736748279627979) 2025-07-14 12:32:26 UTC 2623 followers, XXX engagements "$QDEL QuidelOrtho and BHLMANN Laboratories AG introduce FCAL Turbo and FPELA Turbo assays on Vitros Systems as a MicroTip Partnership Assay. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1944721663209406548) 2025-07-14 11:32:30 UTC 2623 followers, XXX engagements "$ZVRA Zevra Therapeutics to present MIPLYFFA and OLPRUVA at SERGG Annual Meeting. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1946178701269611001) 2025-07-18 12:02:15 UTC 2619 followers, XXX engagements "First patient dosed in Phase X trial of MOMA-341 a potent Werner Helicase Inhibitor by MOMA Therapeutics. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945823939143602495) 2025-07-17 12:32:33 UTC 2613 followers, XXX engagements "🚀🚨 BIOPHARM CATALYST ALERT 📆 $INCY Incyte will present Phase X Myelofibrosis Data for INCB-057643 (BET Inhibitor - Small Molecule) tomorrow 👀"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1933482572371407048) 2025-06-13 11:12:22 UTC 2613 followers, XXX engagements "$HCM HUTCHMED announces China approval for ORPATHYS + TAGRISSO combo in treating lung cancer patients with MET amplification after EGFR inhibitor therapy. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1939602892316639577) 2025-06-30 08:32:20 UTC 2614 followers, XXX engagements "$OTLC SAPU Bioscience highlights study linking TGFB2 to survival in younger pancreatic cancer patients in peer-reviewed publication. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1946020309389463688) 2025-07-18 01:32:51 UTC 2613 followers, XXX engagements "$SILO Silo Pharma finishes dosing in safety study for PTSD drug SPC-15. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945469361902555147) 2025-07-16 13:03:35 UTC 2613 followers, XXX engagements "$KRRO KRRO-110 from Korro granted Orphan Drug Designation by European Medicines Agency. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947273440945451053) 2025-07-21 12:32:21 UTC 2620 followers, XXX engagements "$IDYA IDEAYA and Hengrui reveal IDE849 for IASLC 2025. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947711300655845785) 2025-07-22 17:32:15 UTC 2623 followers, XXX engagements "Cloudbreak Pharma Inc. reports encouraging Phase X findings for CBT-004 in patients with Vascularized Pinguecula. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947092204708855966) 2025-07-21 00:32:11 UTC 2622 followers, XXX engagements "$TLSA Tiziana Life Sciences reveals immune system analysis of nasal Foralumab in patients with moderate Alzheimer's disease. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947258337080566036) 2025-07-21 11:32:20 UTC 2622 followers, XXX engagements "Revalesio has published results of RESCUE Phase X Trial evaluating RNS60 as additional therapy for Acute Ischemic Stroke in Stroke journal. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947273415712534923) 2025-07-21 12:32:15 UTC 2620 followers, XXX engagements "$IMAB I-Mab acquires Bridge Health to enhance Givastomig IP portfolio. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945808968561160397) 2025-07-17 11:33:04 UTC 2615 followers, XXX engagements "$SWTX European Commission conditionally approves EZMEKLY (mirdametinib) for treating NF1-PN in adult and pediatric patients. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1946239709015085116) 2025-07-18 16:04:40 UTC 2613 followers, 1008 engagements "Polivy (polatuzumab vedotin) by Roche Canada is now publicly reimbursed in Quebec for first-line treatment of large B-cell lymphoma in adults. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947650899213750497) 2025-07-22 13:32:14 UTC 2622 followers, XXX engagements "$AUTL European Marketing Authorization approved for Autolus Therapeutics' CAR T therapy AUCATZYL for adults (26+) with relapsed or refractory B-ALL. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947258343313314024) 2025-07-21 11:32:22 UTC 2622 followers, XXX engagements "$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X results for ABTECT 8-week induction trials of Obefazimod in treating moderate to severe ulcerative colitis. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947816984931868798) 2025-07-23 00:32:12 UTC 2623 followers, XXX engagements "$KALV KalVista Pharmaceuticals has received UK MHRA approval for EKTERLY (sebetralstat) the first and only oral on-demand treatment for Hereditary Angioedema. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945219941680210053) 2025-07-15 20:32:29 UTC 2616 followers, XXX engagements "$REPL FDA issues Complete Response Letter to Replimune for RP1 Biologics License Application for Advanced Melanoma treatment. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947620700803792908) 2025-07-22 11:32:14 UTC 2623 followers, 1115 engagements "$PTGX Protagonist submits NDA for first Icotrokinra FDA approval aiming to revolutionize plaque psoriasis treatment for adults and adolescents. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947273421307691354) 2025-07-21 12:32:16 UTC 2615 followers, XXX engagements "FDA grants Orphan Drug Designation to ImCheck's ICT01 for treating Acute Myeloid Leukemia. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1946141009383215200) 2025-07-18 09:32:28 UTC 2613 followers, XXX engagements "$CVRX CVRx reports positive update on Barostim outpatient payment. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945453987358195724) 2025-07-16 12:02:30 UTC 2610 followers, XXX engagements "$IONS New study in JACI In Practice shows how donidalorsen benefits HAE patients who switched from other treatments in Phase X OASISplus data. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947258350670127142) 2025-07-21 11:32:23 UTC 2623 followers, XXX engagements "$RHHBY Genentech updates on Astegolimab in COPD. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947167696304718306) 2025-07-21 05:32:10 UTC 2623 followers, XXX engagements "$BIIB STOK Stoke Therapeutics and Biogen will present data on Zorevunersen an investigational medicine for Dravet syndrome at the EPNS Congress. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1943272651973390769) 2025-07-10 11:34:39 UTC 2622 followers, XXX engagements "$PRAX Praxis Precision Medicines granted FDA Breakthrough Therapy Designation for Relutrigine to treat seizures related to SCN2A and SCN8A Developmental and Epileptic Encephalopathies. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945823930666934771) 2025-07-17 12:32:31 UTC 2616 followers, XXX engagements "$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X trials for ABTECT 8-week induction using Obefazimod for moderate to severe ulcerative colitis a first-of-its-kind oral miR-124 enhancer. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947771757282398451) 2025-07-22 21:32:29 UTC 2623 followers, XXX engagements "Pharma/Biotech Highlights: $RVVTF: Revive develops new formulation for bucillamine. $GERN: Geron schedules Imetelstat NDA's PDUFA. $SLS: Data monitoring committee recommends continuing Galinpepimut-S trial. $LLY: Lilly's Retevmo triumphs treating thyroid cancer"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1694082191351762945) 2023-08-22 20:20:43 UTC 2613 followers, XXX engagements "$CGTX Cognition Therapeutics releases study examining how Zervimesine shields neurons and synapses in Alzheimer's disease. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947265857270534315) 2025-07-21 12:02:13 UTC 2622 followers, XXX engagements "$CGTX Cognition Therapeutics will present positive clinical data from CT1812 Phase X study in DLB at AAIC in a podium presentation. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945453980051726630) 2025-07-16 12:02:28 UTC 2620 followers, XXX engagements "$IRON Disc Medicine confirms plan to submit NDA for Bitopertin in EPP in October 2025 after positive pre-NDA meeting announcement. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947273409840488919) 2025-07-21 12:32:14 UTC 2620 followers, XXX engagements "$IMAB I-Mab releases Givastomig Monotherapy Data in Clinical Cancer Research. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1939784175571345836) 2025-06-30 20:32:41 UTC 2615 followers, XXX engagements "$ATYR aTyr Pharma reports completion of Phase X EFZO-FIT study of Efzofitimod in patients with pulmonary sarcoidosis. Last patient visit announced. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947628237364072806) 2025-07-22 12:02:11 UTC 2623 followers, XXX engagements "Eisai to share four-year efficacy and safety results for continuous treatment with lecanemab at Alzheimer's Association International Conference 2025. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947447166949331097) 2025-07-22 00:02:41 UTC 2622 followers, XXX engagements "$BMY Bristol Myers Squibb reports Phase X INDEPENDENCE Trial topline findings for Reblozyl in adults with Myelofibrosis-Associated Anemia. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1946163606707667256) 2025-07-18 11:02:16 UTC 2613 followers, XXX engagements "$RHHBY Genentech updates on FDA application for Columvi combo for patients with relapsed or refractory Diffuse Large B-cell Lymphoma. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1946239716480963035) 2025-07-18 16:04:42 UTC 2622 followers, 1679 engagements "$RPTX Repare Therapeutics and Debiopharm have signed an exclusive global licensing deal for Lunresertib. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945219932716970213) 2025-07-15 20:32:27 UTC 2610 followers, XXX engagements "$GILD Gilead shares new research on lenacapavir's effectiveness for HIV prevention at IAS 2025. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1944759376243544306) 2025-07-14 14:02:21 UTC 2622 followers, XXX engagements "$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X outcomes for ABTECT 8-Week trial on Obefazimod for Ulcerative Colitis. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947779263241101458) 2025-07-22 22:02:19 UTC 2623 followers, XXX engagements "$GMAB Genmab reports DARZALEX (daratumumab) net sales for Q2 2025. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945431290842664995) 2025-07-16 10:32:18 UTC 2610 followers, XXX engagements "Eisai will share four-year efficacy and safety data on continuous treatment with Lecanemab at the Alzheimer's Association International Conference 2025. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947567825000009931) 2025-07-22 08:02:08 UTC 2622 followers, XXX engagements "$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X trial results for ABTECT 8-week induction studies on Obefazimod a unique oral miR-124 enhancer for ulcerative colitis. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947847592425230474) 2025-07-23 02:33:49 UTC 2623 followers, XXX engagements "$ADAG Adagene provides regulatory update on clinical plan for Muzastotug in microsatellite stable colorectal cancer after successful FDA meeting. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945076458277495035) 2025-07-15 11:02:20 UTC 2623 followers, XXX engagements "$HIMS Securities class actions initiated against Hims & Hers Health Inc. (HIMS) for alleged deceptive marketing of Wegovy. Investors with losses urged to contact Hagens Berman. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945929694886662219) 2025-07-17 19:32:47 UTC 2613 followers, XXX engagements "$OKYO OKYO Pharma secures $1.9M in non-dilutive funding to speed up Urcosimod development for Neuropathic Corneal Pain. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945831540661047685) 2025-07-17 13:02:45 UTC 2613 followers, XXX engagements "ImCheck's ICT01 has received Orphan Drug Designation from the EMA for treating Acute Myeloid Leukemia. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947258362594537729) 2025-07-21 11:32:26 UTC 2615 followers, XXX engagements "$OTLC Oncotelic Therapeutics points to study linking TGFB2 to survival in younger pancreatic cancer patients in new publication. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945869179351171556) 2025-07-17 15:32:19 UTC 2613 followers, XXX engagements "$RCKT Rocket Pharmaceuticals gets FDA RMAT Designation for RP-A601 gene therapy for PKP2-Arrhythmogenic Cardiomyopathy. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945808976576409769) 2025-07-17 11:33:06 UTC 2613 followers, XXX engagements "AusperBio has obtained China CDE approval to progress AHB-137 to Phase III clinical trial for Chronic Hepatitis B treatment. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947386667628957812) 2025-07-21 20:02:16 UTC 2623 followers, XXX engagements "$ZVRA Zevra Therapeutics reveals data from open label extension proving MIPLYFFA's long-term effectiveness in treating NPC published in Journal of Molecular Genetics and Metabolism. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945453971688288631) 2025-07-16 12:02:26 UTC 2610 followers, XXX engagements "$IVBIY Innovent Biologics to present updated data on IBI363 a novel PD-1/IL-2-bias Bispecific Antibody Fusion Protein in advanced Non-small Cell Lung Cancer at 2025 ASCO Meeting. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1930060038770700789) 2025-06-04 00:32:26 UTC 2613 followers, XXX engagements "$MTVA MetaVia has administered the first patient in the XX mg MAD cohort of its Phase X clinical trial testing DA-1726 for obesity treatment to determine the maximum tolerated dose. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1942932313215832503) 2025-07-09 13:02:16 UTC 2610 followers, XXX engagements "Spherix Global Insights reports GSK's Linerixibat set to help with unmet needs in treating pruritus linked to Primary Biliary Cholangitis. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945899455003455996) 2025-07-17 17:32:37 UTC 2623 followers, XXX engagements "$AZN TAGRISSO combined with chemotherapy showed significant and meaningful enhancement in overall survival for EGFR-mutated advanced lung cancer. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947258330034139213) 2025-07-21 11:32:18 UTC 2622 followers, XXX engagements "$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X results for ABTECT 8-Week Induction Trials of Obefazimod in patients with moderate to severe ulcerative colitis. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947801890529677601) 2025-07-22 23:32:13 UTC 2623 followers, XXX engagements "$ENSC Ensysce Biosciences starts Phase X trial for PF614 a new opioid for pain relief with abuse deterrent properties. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945461522312069208) 2025-07-16 12:32:26 UTC 2610 followers, XXX engagements "$PARIS:COX PARIS:FR Nicox and Kowa ink deal worth XXXXX million granting exclusive rights to Glaucoma Treatment NCX XXX in U.S. and unlicensed territories. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945718204485284319) 2025-07-17 05:32:24 UTC 2612 followers, XXX engagements "$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X outcomes in ABTECT 8-Week trials for Obefazimod a novel miR-124 enhancer for treatment of Ulcerative Colitis. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947824536189342085) 2025-07-23 01:02:12 UTC 2623 followers, XXX engagements "GenSight Biologics reports study results on factors predicting final visual outcome in patients who received LUMEVOQ gene therapy. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945831532326990138) 2025-07-17 13:02:43 UTC 2613 followers, XXX engagements "Akeso has enrolled the first patient in Phase III trial (AK112-312/HARMONi-GI6) for Ivonescimab in advanced metastatic colorectal cancer treatment. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945302953881165975) 2025-07-16 02:02:20 UTC 2613 followers, XXX engagements "$ENVB Enveric Biosciences' top drug candidate EB-003 shows promise in preclinical PTSD model with positive effects. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945114198767514092) 2025-07-15 13:32:18 UTC 2623 followers, 2741 engagements "$CYTK Cytokinetics reveals five presentations on Aficamten at ESC Congress 2025. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1943272645786767545) 2025-07-10 11:34:37 UTC 2620 followers, XXX engagements "$BRCTF New data on Lecanemab's effectiveness and safety over four years will be shared at AAIC 2025. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947545231177748678) 2025-07-22 06:32:21 UTC 2622 followers, XXX engagements "$ORKA Oruka Therapeutics gets IND clearance for EVERLAST-A Phase 2a trial of ORKA-001 in Psoriasis. Phase X data to be detailed at EADV in September. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947258375143817664) 2025-07-21 11:32:29 UTC 2615 followers, XXX engagements "$OCGN First patient dosed in Phase 2/3 GARDian3 trial for OCU410ST a gene therapy candidate for Stargardt Disease announced by Ocugen Inc. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1946171170883252410) 2025-07-18 11:32:19 UTC 2613 followers, 1224 engagements "$JNJ Johnson & Johnson aims for US FDA approval of icotrokinra to change treatment for adults and teens with plaque psoriasis. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947280960367804609) 2025-07-21 13:02:14 UTC 2620 followers, XXX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@OzmosiHealth Ozmosi
Ozmosi posts on X about more info, $pph, $xph, $ibb the most. They currently have XXXXX followers and XXX posts still getting attention that total XXXXXX engagements in the last XX hours.
Engagements: XXXXXX #
- X Week XXXXXX +84%
- X Month XXXXXXX +41%
- X Months XXXXXXX +7.10%
- X Year XXXXXXXXX +82%
Mentions: XX #
- X Month XXX -XX%
- X Months XXXXX +20%
- X Year XXXXX +61%
Followers: XXXXX #
- X Week XXXXX +8.80%
- X Month XXXXX +11%
- X Months XXXXX +24%
- X Year XXXXX +42%
CreatorRank: XXXXXXX #
Social Influence #
Social category influence stocks XXXX% countries XXXX% currencies XXXX% cryptocurrencies XXXX% finance XXXX%
Social topic influence more info #96, $pph #1, $xph #1, $ibb #1, $xbi #1, $abvx #6, $rhhby 0.41%, $cytk 0.41%, canada 0.41%, $ivbiy XXXX%
Top accounts mentioned or mentioned by @marketwirenews @salmanfirat2 @towiu2 @john06746191 @stewdomer @dwill3000 @chrismangum14 @nicolem52807658 @mitchellreed09
Top assets mentioned Bitcoin Incognito (XBI) Cytokinetics Inc. (CYTK) Crinetics Pharmaceuticals, Inc. (CRNX) Bristol-Myers Squibb Co (BMY) Biogen Inc (BIIB) Halozyme Therapeutics, Inc. (HALO) Merck & Co., Inc. (MRK) Krystal Biotech, Inc. Common Stock (KRYS) Neurocrine Biosciences, Inc. (NBIX) Alnylam Pharmaceuticals, Inc. (ALNY) Madrigal Pharmaceuticals, Inc. Common Stock (MDGL) SuperRare (RARE) Corcept Therapeutics Inc. (CORT) QuidelOrtho Corporation Common Stock (QDEL) Incyte Corporation (INCY) IDEAYA Biosciences, Inc. Common Stock (IDYA) SpringWorks Therapeutics, Inc. Common Stock (SWTX) Protagonist Therapeutics, Inc (PTGX) Ionis Pharmaceuticals, Inc. Common Stock (IONS) Eli Lilly and Company (LLY) Geron Corp (GERN) Gilead Sciences, Inc. (GILD) Hims & Hers Health, Inc. (HIMS) AstraZeneca PLC (AZN)
Top Social Posts #
Top posts by engagements in the last XX hours
"HanchorBio moves forward with global impact of HCB101 immunotherapy. Listed on TPEx. More Info: $XBI $IBB $XPH $PPH"
@OzmosiHealth on X 2025-07-16 13:32:24 UTC 2610 followers, XXX engagements
"$CRDL TSX:CRDL Cardiol Therapeutics locks database for Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-22 11:32:11 UTC 2622 followers, XXX engagements
"$RHHBY Roche's latest announcement provides an update on the use of astegolimab in treating chronic obstructive pulmonary disease in accordance with Art. XX LR. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-21 06:02:38 UTC 2623 followers, XXX engagements
"$NRSN Join Aaron Lazar and NeuroSense CEO Alon Ben-Noon in a live podcast discussing ALS science PrimeC's strategies and community impact. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-22 13:02:11 UTC 2623 followers, XXX engagements
"$CRNX Crinetics will present new long-term data showing lasting control of oral PALSONIFY in Acromegaly at ENDO 2025. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-13 22:02:14 UTC 2613 followers, XXX engagements
"$BMY Bristol Myers Squibb's sNDA for Sotyktu (deucravacitinib) in treating active Psoriatic Arthritis accepted for review in four regions worldwide. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-21 11:02:05 UTC 2615 followers, XXX engagements
"$HALO Halozyme reports argenx gains EU approval for VYVGART subcutaneous injection with ENHANZE to treat CIDP. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-06-20 17:33:32 UTC 2619 followers, XXX engagements
"WHO adds ArkBio's Ziresovir to list of priority drugs for pediatric RSV. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-16 01:32:22 UTC 2610 followers, XXX engagements
"$OKYO OKYO Pharma announces promising Phase X trial data for Urcosimod in treating Neuropathic Corneal Pain. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-16 13:32:22 UTC 2613 followers, XXX engagements
"🚀🚨 BIOPHARM CATALYST ALERT 📆 $CRNX Crinetics will present Phase X Adrenal Hyperplasia Congenital Data for Atumelnant (MCR Antagonist - Small Molecule) tomorrow 👀" @OzmosiHealth on X 2025-07-11 11:12:20 UTC 2623 followers, XXX engagements
"Fast-track designation granted by FDA for DualityBio's Next-Generation HER3 ADC DB-1310. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-22 02:32:28 UTC 2622 followers, XXX engagements
"$APTOF TSX:APS Aptose gets second advance from Hanmi Pharmaceutical for Tuspetinib development in AML triplet therapy. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-15 21:32:25 UTC 2620 followers, XXX engagements
"$CYTK Cytokinetics reveals more info on Aficamten at ESC Heart Failure 2025 Congress. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-05-18 12:32:30 UTC 2622 followers, 1167 engagements
"$ONCY TSX:ONC Oncolytics Biotech showcases translated data showing Pelareorep's effectiveness in various tumor types. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-16 13:03:32 UTC 2613 followers, XXX engagements
"$ELDN New findings from Eledon Pharmaceuticals' Phase 1b trial of Tegoprubart in kidney transplant patients will be shared at World Transplant Congress 2025. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-17 20:32:55 UTC 2616 followers, XXX engagements
"$OGEN Oragenics Inc. reveals drug manufacturing deal in the U.S. to aid ONP-002 clinical progress. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-16 13:03:37 UTC 2615 followers, XXX engagements
"$ALDX Aldeyra Therapeutics' NDA for Reproxalap in treating Dry Eye Disease accepted by FDA for review. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-17 11:32:56 UTC 2613 followers, XXX engagements
"$MRK Health Canada approved KEYTRUDA to treat adult patients with FIGO 2014 Stage III-IVA cervical cancer alongside chemoradiotherapy (CRT). More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-21 15:32:12 UTC 2623 followers, XXX engagements
"$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X trials of Obefazimod in treating moderate-severe ulcerative colitis. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-23 01:32:42 UTC 2623 followers, XXX engagements
"$IVBIY In 2025 Innovent Biologics will present updated data on IBI363 (PD-1/IL-2-bias Bispecific Antibody Fusion Protein) in Phase X trials for advanced colorectal cancer. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-06-02 00:32:48 UTC 2622 followers, XXX engagements
"$KRYS First patient dosed in Phase 1/2 trial of KB801 for Neurotrophic Keratitis treatment announces Krystal Biotech. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-09 11:32:37 UTC 2614 followers, XXX engagements
"$AQST Aquestive Therapeutics announces update on international expansion for Anaphylm (epinephrine) Sublingual Film. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-15 11:02:21 UTC 2623 followers, XXX engagements
"Sun Pharma introduces LEQSELVI (deuruxolitinib) in the US for severe Alopecia Areata treatment. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-14 11:32:26 UTC 2614 followers, XXX engagements
"$SXTP SXTPW XX Degrees Pharmaceuticals and Tulane University collaborate for research on Tafenoquine against Lyme and Bartonella bacteria. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-17 12:32:27 UTC 2616 followers, XXX engagements
"$LTRN Lantern Pharma gets EU patent for LP-284 strengthening global IP for AI-designed cancer treatment. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-21 12:32:19 UTC 2622 followers, XXX engagements
"$ARGX argenx progresses clinical development of ARGX-119 for Congenital Myasthenic Syndromes. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-06-30 05:32:38 UTC 2613 followers, XXX engagements
"$CGEN First patient dosed in COM701 Global Platform Trial for Platinum Sensitive Ovarian Cancer announced by Compugen. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-21 11:32:25 UTC 2614 followers, XXX engagements
"Ultomiris drug market projected to reach USD XXXXX billion by 2034 with a CAGR of 31.52%. Report covers analysis trends forecast segmentation growth rate and SWOT analysis. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-16 04:32:29 UTC 2610 followers, XXX engagements
"$IVBIY Phase X results of Innovent Biologics' IBI343 for advanced gastric/esophageal adenocarcinoma published in Nature Medicine. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-17 00:32:21 UTC 2620 followers, XXX engagements
"AGT announces promising results from AGT103-T HIV Functional Cure Program presented as late-breaker at International AIDS Society 2025. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-22 15:32:26 UTC 2623 followers, XXX engagements
"$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X outcomes for ABTECT trials on Obefazimod an oral miR-124 enhancer for moderate to severe ulcerative colitis. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-23 02:02:42 UTC 2623 followers, XXX engagements
"$NBIX Neurocrine Biosciences reveals 1-year data demonstrating sustained effectiveness of CRENESSITY (crinecerfont) in adult patients at ENDO 2025. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-14 13:02:23 UTC 2622 followers, XXX engagements
"$ABVX PARIS:ABVX PARIS:FR Abivax reports encouraging Phase X results from ABTECT trials on Obefazimod for moderate to severe ulcerative colitis. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-22 21:02:48 UTC 2623 followers, 1396 engagements
"Nanoscope Therapeutics begins submitting BLA to FDA for MCO-010 the first gene-agnostic therapy for Retinitis Pigmentosa. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-14 11:32:33 UTC 2614 followers, XXX engagements
"$RDHL FDA provides positive feedback on RedHill's pathway for approval of RHB-204 for Crohn's Disease a groundbreaking treatment. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-21 13:32:20 UTC 2615 followers, XXX engagements
"$FBIO MBIO U.S. FDA grants Orphan Drug Designation to Mustang Bio for MB-101 to treat Astrocytomas and Glioblastoma with IL13Ra2-targeted CAR T-cells. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-07 13:02:18 UTC 2613 followers, XXX engagements
"$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X results in ABTECT trials for Obefazimod in moderate to severe ulcerative colitis. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-23 00:02:13 UTC 2623 followers, XXX engagements
"$BRCTF Lecanemab's drug discovery research receives 9th Bioindustry Award from Japan Bioindustry Association. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-16 08:02:15 UTC 2610 followers, XXX engagements
"$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X outcomes in ABTECT trials using Obefazimod for ulcerative colitis. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-22 23:02:21 UTC 2623 followers, XXX engagements
"$BIIB STOK Biogen and Stoke Therapeutics will share data on Zorevunersen for Dravet syndrome at the EPNS Congress. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-10 12:02:29 UTC 2622 followers, XXX engagements
"DCA opens today to enhance Asia's data center network. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-21 10:32:17 UTC 2620 followers, XXX engagements
"$KMSTF NLSP NLS Pharmaceutics reports progress in iTOL-102 program as BIRD Foundation approves payment to Kadimastem and iTolerance for Type X Diabetes therapy development. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-17 11:33:02 UTC 2613 followers, XXX engagements
"$HOTH Hoth Therapeutics partners with VA for GDNF research targeting obesity and fatty liver. Study underway comparing GDNF to Semaglutide. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-22 12:32:16 UTC 2623 followers, XXX engagements
"$PMN U.S. FDA grants ProMIS Neurosciences Fast Track Designation for PMN310 in Alzheimer's Disease treatment. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-21 12:32:18 UTC 2620 followers, XXX engagements
"Reunion Neuroscience reports publication of RE104 Phase X Data in The Journal of Clinical Psychopharmacology. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-22 11:32:12 UTC 2622 followers, XXX engagements
"First patient enrolled in Phase 2a trial of 4P004 by Moving Biotech for knee osteoarthritis. 4P004 is a potential first-in-class GLP-1 therapy. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-16 05:02:16 UTC 2613 followers, XXX engagements
"🚀🚨 BIOPHARM CATALYST ALERT 📆 $CYTK Cytokinetics will present P3 Cardiomyopathy Hypertrophic Data for Aficamten (MYBPC3 Inhibitor - Small Molecule) tomorrow 👀" @OzmosiHealth on X 2025-05-17 11:12:21 UTC 2622 followers, XXX engagements
"Genascence receives FDA approval for GNSC-001 as a Regenerative Medicine Advanced Therapy for Knee Osteoarthritis (OA) in the U.S. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-16 12:02:31 UTC 2610 followers, XXX engagements
"$RCKT RCKT stock plunges due to FDA Clinical Hold on RP-A501 trial sparking Class Action by Hagens Berman. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-17 19:32:49 UTC 2613 followers, XXX engagements
"$GLUE Phase X study of MRT-8102 a NEK7-Directed Molecular Glue Degrader for treating inflammatory diseases begins with dosing of first subjects by Monte Rosa Therapeutics. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-21 11:32:28 UTC 2615 followers, XXX engagements
"$CASI CASI Pharmaceuticals names David Cory as CEO to lead U.S. company focusing on CID-103 clinical development a promising Anti-CD38 program. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-21 20:32:23 UTC 2622 followers, XXX engagements
"$AGEN GSK GSK's SHINGRIX now approved by US FDA in prefilled syringe. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-17 11:32:58 UTC 2613 followers, XXX engagements
"$ASND Updated Phase X results show continued positive response to TransCon PTH treatment for adults with hypoparathyroidism with benefits in biochemistries kidney function and quality of life. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-14 20:32:25 UTC 2607 followers, XXX engagements
"$ALNY OXLUMO (lumasiran injection) is now reimbursed in Canada for treating Primary Hyperoxaluria Type X (PH1) in pediatric and adult patients. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-02 17:03:18 UTC 2613 followers, XXX engagements
"$MDGL Madrigal Pharmaceuticals has been granted a new U.S. patent by the Patent and Trademark Office for Rezdiffra (Resmetirom). More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-16 12:32:23 UTC 2613 followers, XXX engagements
"Government endorses SNB-101 as promising Small Cell Lung Cancer therapy. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-16 12:32:24 UTC 2610 followers, XXX engagements
"$RARE Ultragenyx gets Breakthrough Therapy status for GTX-102 in Angelman Syndrome. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-06-27 12:32:25 UTC 2622 followers, XXX engagements
"Diakonos Oncology reports first patient dosed in Phase X trial of DOC1021 for Glioblastoma. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-22 12:32:19 UTC 2622 followers, XXX engagements
"ReAlta Life Sciences releases data showing RLS-0071 decreases brain inflammation in preclinical hypoxic ischemic encephalopathy model. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-22 12:32:18 UTC 2622 followers, XXX engagements
"$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X outcomes for ABTECT trials on Obefazimod in treating Ulcerative Colitis. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-22 22:32:19 UTC 2623 followers, XXX engagements
"$KROS Keros Therapeutics initiates Phase X RENEW Clinical Trial of Elritercept with first patient dosing announced. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-17 12:32:29 UTC 2613 followers, XXX engagements
"$KZR FDA lifted partial clinical hold on PORTOLA Phase 2a Trial of Zetomipzomib for Autoimmune Hepatitis by Kezar Life Sciences. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-15 21:02:20 UTC 2610 followers, XXX engagements
"First patient dosed by OncoC4 with potential best-in-class PD-1/VEGF bispecific antibody AI-081 in Phase X of BIPAVE-001 trial for solid tumors in US. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-22 11:32:16 UTC 2622 followers, XXX engagements
"$CORT New Drug Application submitted by Corcept for Relacorilant intended for patients with Platinum-Resistant Ovarian Cancer. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-14 12:32:26 UTC 2623 followers, XXX engagements
"$QDEL QuidelOrtho and BHLMANN Laboratories AG introduce FCAL Turbo and FPELA Turbo assays on Vitros Systems as a MicroTip Partnership Assay. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-14 11:32:30 UTC 2623 followers, XXX engagements
"$ZVRA Zevra Therapeutics to present MIPLYFFA and OLPRUVA at SERGG Annual Meeting. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-18 12:02:15 UTC 2619 followers, XXX engagements
"First patient dosed in Phase X trial of MOMA-341 a potent Werner Helicase Inhibitor by MOMA Therapeutics. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-17 12:32:33 UTC 2613 followers, XXX engagements
"🚀🚨 BIOPHARM CATALYST ALERT 📆 $INCY Incyte will present Phase X Myelofibrosis Data for INCB-057643 (BET Inhibitor - Small Molecule) tomorrow 👀" @OzmosiHealth on X 2025-06-13 11:12:22 UTC 2613 followers, XXX engagements
"$HCM HUTCHMED announces China approval for ORPATHYS + TAGRISSO combo in treating lung cancer patients with MET amplification after EGFR inhibitor therapy. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-06-30 08:32:20 UTC 2614 followers, XXX engagements
"$OTLC SAPU Bioscience highlights study linking TGFB2 to survival in younger pancreatic cancer patients in peer-reviewed publication. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-18 01:32:51 UTC 2613 followers, XXX engagements
"$SILO Silo Pharma finishes dosing in safety study for PTSD drug SPC-15. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-16 13:03:35 UTC 2613 followers, XXX engagements
"$KRRO KRRO-110 from Korro granted Orphan Drug Designation by European Medicines Agency. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-21 12:32:21 UTC 2620 followers, XXX engagements
"$IDYA IDEAYA and Hengrui reveal IDE849 for IASLC 2025. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-22 17:32:15 UTC 2623 followers, XXX engagements
"Cloudbreak Pharma Inc. reports encouraging Phase X findings for CBT-004 in patients with Vascularized Pinguecula. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-21 00:32:11 UTC 2622 followers, XXX engagements
"$TLSA Tiziana Life Sciences reveals immune system analysis of nasal Foralumab in patients with moderate Alzheimer's disease. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-21 11:32:20 UTC 2622 followers, XXX engagements
"Revalesio has published results of RESCUE Phase X Trial evaluating RNS60 as additional therapy for Acute Ischemic Stroke in Stroke journal. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-21 12:32:15 UTC 2620 followers, XXX engagements
"$IMAB I-Mab acquires Bridge Health to enhance Givastomig IP portfolio. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-17 11:33:04 UTC 2615 followers, XXX engagements
"$SWTX European Commission conditionally approves EZMEKLY (mirdametinib) for treating NF1-PN in adult and pediatric patients. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-18 16:04:40 UTC 2613 followers, 1008 engagements
"Polivy (polatuzumab vedotin) by Roche Canada is now publicly reimbursed in Quebec for first-line treatment of large B-cell lymphoma in adults. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-22 13:32:14 UTC 2622 followers, XXX engagements
"$AUTL European Marketing Authorization approved for Autolus Therapeutics' CAR T therapy AUCATZYL for adults (26+) with relapsed or refractory B-ALL. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-21 11:32:22 UTC 2622 followers, XXX engagements
"$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X results for ABTECT 8-week induction trials of Obefazimod in treating moderate to severe ulcerative colitis. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-23 00:32:12 UTC 2623 followers, XXX engagements
"$KALV KalVista Pharmaceuticals has received UK MHRA approval for EKTERLY (sebetralstat) the first and only oral on-demand treatment for Hereditary Angioedema. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-15 20:32:29 UTC 2616 followers, XXX engagements
"$REPL FDA issues Complete Response Letter to Replimune for RP1 Biologics License Application for Advanced Melanoma treatment. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-22 11:32:14 UTC 2623 followers, 1115 engagements
"$PTGX Protagonist submits NDA for first Icotrokinra FDA approval aiming to revolutionize plaque psoriasis treatment for adults and adolescents. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-21 12:32:16 UTC 2615 followers, XXX engagements
"FDA grants Orphan Drug Designation to ImCheck's ICT01 for treating Acute Myeloid Leukemia. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-18 09:32:28 UTC 2613 followers, XXX engagements
"$CVRX CVRx reports positive update on Barostim outpatient payment. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-16 12:02:30 UTC 2610 followers, XXX engagements
"$IONS New study in JACI In Practice shows how donidalorsen benefits HAE patients who switched from other treatments in Phase X OASISplus data. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-21 11:32:23 UTC 2623 followers, XXX engagements
"$RHHBY Genentech updates on Astegolimab in COPD. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-21 05:32:10 UTC 2623 followers, XXX engagements
"$BIIB STOK Stoke Therapeutics and Biogen will present data on Zorevunersen an investigational medicine for Dravet syndrome at the EPNS Congress. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-10 11:34:39 UTC 2622 followers, XXX engagements
"$PRAX Praxis Precision Medicines granted FDA Breakthrough Therapy Designation for Relutrigine to treat seizures related to SCN2A and SCN8A Developmental and Epileptic Encephalopathies. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-17 12:32:31 UTC 2616 followers, XXX engagements
"$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X trials for ABTECT 8-week induction using Obefazimod for moderate to severe ulcerative colitis a first-of-its-kind oral miR-124 enhancer. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-22 21:32:29 UTC 2623 followers, XXX engagements
"Pharma/Biotech Highlights: $RVVTF: Revive develops new formulation for bucillamine. $GERN: Geron schedules Imetelstat NDA's PDUFA. $SLS: Data monitoring committee recommends continuing Galinpepimut-S trial. $LLY: Lilly's Retevmo triumphs treating thyroid cancer" @OzmosiHealth on X 2023-08-22 20:20:43 UTC 2613 followers, XXX engagements
"$CGTX Cognition Therapeutics releases study examining how Zervimesine shields neurons and synapses in Alzheimer's disease. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-21 12:02:13 UTC 2622 followers, XXX engagements
"$CGTX Cognition Therapeutics will present positive clinical data from CT1812 Phase X study in DLB at AAIC in a podium presentation. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-16 12:02:28 UTC 2620 followers, XXX engagements
"$IRON Disc Medicine confirms plan to submit NDA for Bitopertin in EPP in October 2025 after positive pre-NDA meeting announcement. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-21 12:32:14 UTC 2620 followers, XXX engagements
"$IMAB I-Mab releases Givastomig Monotherapy Data in Clinical Cancer Research. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-06-30 20:32:41 UTC 2615 followers, XXX engagements
"$ATYR aTyr Pharma reports completion of Phase X EFZO-FIT study of Efzofitimod in patients with pulmonary sarcoidosis. Last patient visit announced. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-22 12:02:11 UTC 2623 followers, XXX engagements
"Eisai to share four-year efficacy and safety results for continuous treatment with lecanemab at Alzheimer's Association International Conference 2025. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-22 00:02:41 UTC 2622 followers, XXX engagements
"$BMY Bristol Myers Squibb reports Phase X INDEPENDENCE Trial topline findings for Reblozyl in adults with Myelofibrosis-Associated Anemia. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-18 11:02:16 UTC 2613 followers, XXX engagements
"$RHHBY Genentech updates on FDA application for Columvi combo for patients with relapsed or refractory Diffuse Large B-cell Lymphoma. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-18 16:04:42 UTC 2622 followers, 1679 engagements
"$RPTX Repare Therapeutics and Debiopharm have signed an exclusive global licensing deal for Lunresertib. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-15 20:32:27 UTC 2610 followers, XXX engagements
"$GILD Gilead shares new research on lenacapavir's effectiveness for HIV prevention at IAS 2025. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-14 14:02:21 UTC 2622 followers, XXX engagements
"$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X outcomes for ABTECT 8-Week trial on Obefazimod for Ulcerative Colitis. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-22 22:02:19 UTC 2623 followers, XXX engagements
"$GMAB Genmab reports DARZALEX (daratumumab) net sales for Q2 2025. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-16 10:32:18 UTC 2610 followers, XXX engagements
"Eisai will share four-year efficacy and safety data on continuous treatment with Lecanemab at the Alzheimer's Association International Conference 2025. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-22 08:02:08 UTC 2622 followers, XXX engagements
"$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X trial results for ABTECT 8-week induction studies on Obefazimod a unique oral miR-124 enhancer for ulcerative colitis. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-23 02:33:49 UTC 2623 followers, XXX engagements
"$ADAG Adagene provides regulatory update on clinical plan for Muzastotug in microsatellite stable colorectal cancer after successful FDA meeting. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-15 11:02:20 UTC 2623 followers, XXX engagements
"$HIMS Securities class actions initiated against Hims & Hers Health Inc. (HIMS) for alleged deceptive marketing of Wegovy. Investors with losses urged to contact Hagens Berman. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-17 19:32:47 UTC 2613 followers, XXX engagements
"$OKYO OKYO Pharma secures $1.9M in non-dilutive funding to speed up Urcosimod development for Neuropathic Corneal Pain. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-17 13:02:45 UTC 2613 followers, XXX engagements
"ImCheck's ICT01 has received Orphan Drug Designation from the EMA for treating Acute Myeloid Leukemia. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-21 11:32:26 UTC 2615 followers, XXX engagements
"$OTLC Oncotelic Therapeutics points to study linking TGFB2 to survival in younger pancreatic cancer patients in new publication. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-17 15:32:19 UTC 2613 followers, XXX engagements
"$RCKT Rocket Pharmaceuticals gets FDA RMAT Designation for RP-A601 gene therapy for PKP2-Arrhythmogenic Cardiomyopathy. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-17 11:33:06 UTC 2613 followers, XXX engagements
"AusperBio has obtained China CDE approval to progress AHB-137 to Phase III clinical trial for Chronic Hepatitis B treatment. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-21 20:02:16 UTC 2623 followers, XXX engagements
"$ZVRA Zevra Therapeutics reveals data from open label extension proving MIPLYFFA's long-term effectiveness in treating NPC published in Journal of Molecular Genetics and Metabolism. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-16 12:02:26 UTC 2610 followers, XXX engagements
"$IVBIY Innovent Biologics to present updated data on IBI363 a novel PD-1/IL-2-bias Bispecific Antibody Fusion Protein in advanced Non-small Cell Lung Cancer at 2025 ASCO Meeting. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-06-04 00:32:26 UTC 2613 followers, XXX engagements
"$MTVA MetaVia has administered the first patient in the XX mg MAD cohort of its Phase X clinical trial testing DA-1726 for obesity treatment to determine the maximum tolerated dose. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-09 13:02:16 UTC 2610 followers, XXX engagements
"Spherix Global Insights reports GSK's Linerixibat set to help with unmet needs in treating pruritus linked to Primary Biliary Cholangitis. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-17 17:32:37 UTC 2623 followers, XXX engagements
"$AZN TAGRISSO combined with chemotherapy showed significant and meaningful enhancement in overall survival for EGFR-mutated advanced lung cancer. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-21 11:32:18 UTC 2622 followers, XXX engagements
"$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X results for ABTECT 8-Week Induction Trials of Obefazimod in patients with moderate to severe ulcerative colitis. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-22 23:32:13 UTC 2623 followers, XXX engagements
"$ENSC Ensysce Biosciences starts Phase X trial for PF614 a new opioid for pain relief with abuse deterrent properties. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-16 12:32:26 UTC 2610 followers, XXX engagements
"$PARIS:COX PARIS:FR Nicox and Kowa ink deal worth XXXXX million granting exclusive rights to Glaucoma Treatment NCX XXX in U.S. and unlicensed territories. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-17 05:32:24 UTC 2612 followers, XXX engagements
"$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X outcomes in ABTECT 8-Week trials for Obefazimod a novel miR-124 enhancer for treatment of Ulcerative Colitis. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-23 01:02:12 UTC 2623 followers, XXX engagements
"GenSight Biologics reports study results on factors predicting final visual outcome in patients who received LUMEVOQ gene therapy. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-17 13:02:43 UTC 2613 followers, XXX engagements
"Akeso has enrolled the first patient in Phase III trial (AK112-312/HARMONi-GI6) for Ivonescimab in advanced metastatic colorectal cancer treatment. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-16 02:02:20 UTC 2613 followers, XXX engagements
"$ENVB Enveric Biosciences' top drug candidate EB-003 shows promise in preclinical PTSD model with positive effects. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-15 13:32:18 UTC 2623 followers, 2741 engagements
"$CYTK Cytokinetics reveals five presentations on Aficamten at ESC Congress 2025. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-10 11:34:37 UTC 2620 followers, XXX engagements
"$BRCTF New data on Lecanemab's effectiveness and safety over four years will be shared at AAIC 2025. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-22 06:32:21 UTC 2622 followers, XXX engagements
"$ORKA Oruka Therapeutics gets IND clearance for EVERLAST-A Phase 2a trial of ORKA-001 in Psoriasis. Phase X data to be detailed at EADV in September. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-21 11:32:29 UTC 2615 followers, XXX engagements
"$OCGN First patient dosed in Phase 2/3 GARDian3 trial for OCU410ST a gene therapy candidate for Stargardt Disease announced by Ocugen Inc. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-18 11:32:19 UTC 2613 followers, 1224 engagements
"$JNJ Johnson & Johnson aims for US FDA approval of icotrokinra to change treatment for adults and teens with plaque psoriasis. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-21 13:02:14 UTC 2620 followers, XXX engagements